甲硫氨酸条件性缺乏增加瑞戈非尼对肝癌细胞药物敏感性的研究

doi:10.3969/j.issn.1009-976X.2022.01.004

摘要/Abstract

摘要： 目的探索甲硫氨酸（Met）缺乏对人肝癌（HCC）细胞系HepG2和Huh7的生长影响和甲硫氨酸限制作用是否协同瑞戈非尼抑制肿瘤生长。方法 CCK8实验检测瑞戈非尼分别在正常培养基和甲硫氨酸缺乏的培养基的IC50;凋亡实验、周期实验检测瑞戈非尼在不同培养基条件下对两种肝癌细胞株的凋亡诱导情况和对细胞周期影响;克隆形成实验评估细胞增殖情况;JC-1荧光探针实验检测细胞线粒体膜电位变化;脂质体过氧化实验检测胞内脂质过氧化反应。结果甲硫氨酸缺乏可降低瑞戈非尼在人肝癌细胞株HepG2和Huh7的IC50值;甲硫氨酸缺乏协同瑞戈非尼抑制肿瘤增殖、诱导凋亡、降低线粒体膜电位;而在细胞周期方面对HepG2影响无显著差异;瑞戈非尼和甲硫氨酸限制均可增加HepG2细胞膜脂质过氧化水平,但并无协同作用。结论甲硫氨酸限制和瑞戈非尼在抑制细胞增殖、诱导凋亡等方面起到协同作用;为临床减少瑞戈非尼用药剂量和增加药物敏感性、改善患者生活质量提供体外实验的理论依据。

关键词: 肝癌, 甲硫氨酸, 瑞戈非尼, 药物敏感性

Abstract: Objective To investigate the effects of methionine （Met） deficiency on human hepatocellular carcinoma （HCC） cell lines HepG2 and Huh7 growth, and whether Met deficiency synergizes with regorafenib in tumor growth. Methods IC50 of regorafenib in normal complete medium and methionine-deficient complete medium were detected by CCK8 assay. Apoptosis and cycle flow experiment were employed to identify the apoptosis induction and cell cycle effect of regorafenib on these two cell lines under different medium conditions. Clone formation assay was conducted to explore HCC cell proliferation. Changes of mitochondrial membrane potential were detected by JC-1 fluorescence probe. Liposome peroxidation assay was used to measure lipid peroxidation levels. Results This research revealed that methionine deficiency decreased the IC50 of regorafenib in human hepatocellular carcinoma （HCC） cell lines HepG2 and Huh7. Methionine deficiency synergized with regorafenib in inhibiting tumor proliferation,inducing apoptosis and decreasing mitochondrial membrane potential; while HepG2 cell cycle had no significant effect. Both of them increased but had no synergistic effect on the lipid peroxidation level in HepG2. Conclusion Methionine restriction and regorafenib played a synergistic role in inhibiting cell proliferation, which provided a theoretical basis for clinical treatment on reducing the dose of regorafenib, increasing drug sensitivity and improving patients' quality of life in clinic practice.

Key words: hepatocellular carcinoma, methionine, regorafenib, drug susceptibility

中图分类号:

R735.7

吴烨, 刘晓迪, 许燕妮, 罗葆明. 甲硫氨酸条件性缺乏增加瑞戈非尼对肝癌细胞药物敏感性的研究[J]. 岭南现代临床外科, 2022, 22(01): 24-29.

WU Ye, LIU Xiao-di, XU Yan-ni, LUO Bao-ming. Methionine deficiency increase the drug sensitivity of regorafenibfor hepatocellular carcinoma cells[J]. Lingnan Modern Clinics In Surgery, 2022, 22(01): 24-29.

参考文献

[1] Forner A, Reig M, Bruix J.Hepatocellular carcinoma[J]. Lancet, 2018,391(10127):1301-1314.
[2] Vilgrain V, Pereira H, Assenat E, et al.Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2017,18(12):1624-1636.
[3] Bruix J, Qin S, Merle P, et al.Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017,389(10064):56-66.
[4] Mross K, Frost A, Steinbild S, et al.A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors[J]. Clin Cancer Res, 2012,18(9):2658-2667.
[5] Gao X, Sanderson SM, Dai Z, et al.Dietary methionine influences therapy in mouse cancer models and alters human metabolism[J]. Nature, 2019,572(7769):397-401.
[6] Knott S, Wagenblast E, Khan S, et al.Asparagine bioavailability governs metastasis in a model of breast cancer[J]. Nature, 2018,554(7692):378-381.
[7] Ser Z, Gao X, Johnson C, et al.Targeting one carbon metabolism with an antimetabolite disrupts pyrimidine homeostasis and induces nucleotide overflow[J]. Cell Rep, 2016,15(11):2367-2376.
[8] Maddocks OD, Berkers CR, Mason SM, et al.Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells[J]. Nature, 2013,493(7433):542-546.
[9] Gravel SP, Hulea L, Toban N, et al.Serine deprivation enhances antineoplastic activity of biguanides[J]. Cancer Res, 2014,74(24):7521-7533.
[10] Mentch SJ, Mehrmohamadi M, Huang L, et al.Histone Methylation Dynamics and Gene Regulation Occur through the Sensing of One-Carbon Metabolism[J]. Cell Metab, 2015,22(5):861-873.
[11] Cantor JR, Abu-Remaileh M, Kanarek N, et al.Physiologic Medium Rewires Cellular Metabolism and Reveals Uric Acid as an Endogenous Inhibitor of UMP Synthase[J]. Cell, 2017,169(2):258-272.
[12] Yu C, Huang S, Chang S, et al.The Synergistic Anti-Cancer Effects of NVP-BEZ235 and Regorafenib in Hepatocellular Carcinoma[J]. Molecules, 2020,25(10):2454.
[13] Sanderson SM, Gao X, Dai Z, et al.Methionine metabolism in health and cancer: a nexus of diet and precision medicine[J]. Nature Reviews. Cancer, 2019,19(11):625-637.
[14] 杨梦祺, 刘盼盼, 黄蓬. 肿瘤氧化还原代谢与干预[J]. 中国生化药物杂志, 2016,36(9):16-23.
[15] Cellarier E, Durando X, Vasson MP, et al.Methionine dependency and cancer treatment[J]. Cancer Treat Rev, 2003,29(6):489-499.
[16] Reina-Campos M, Linares JF, Duran A, et al.Increased Serine and One-Carbon Pathway Metabolism by PKClambda/iota Deficiency Promotes Neuroendocrine Prostate Cancer[J]. Cancer Cell, 2019,35(3):385-400.
[17] Kawaguchi K, Miyake K, Han Q, et al.Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived orthotopic xenograft (PDOX) nude mouse model of pancreatic cancer[J]. Cell Cycle, 2018,17(7):868-873.
[18] Xu Q, Li Y, Gao X, et al.HNF4α regulates sulfur amino acid metabolism and confers sensitivity to methionine restriction in liver cancer[J]. Nat Commun, 2020,11(1): 3978.
[19] Cavuoto P, Fenech MF.A review of methionine dependency and the role of methionine restriction in cancer growth control and life-span extension[J]. Cancer Treat Rev, 2012,38(6):726-736.
[20] Yan B, Ai Y, Sun Q, et al.Membrane Damage during Ferroptosis Is Caused by Oxidation of Phospholipids Catalyzed by the Oxidoreductases POR and CYB5R1[J]. Mol Cell, 2021,81(2):355-369.
[21] Li H, Xiao Y, Tang L, et al.Adipocyte fatty acid-binding protein promotes palmitate-induced mitochondrial dysfunction and apoptosis in macrophages[J]. Front Immunol, 2018,9:81.